Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
16.62
-0.10 (-0.60%)
NASDAQ · Last Trade: Apr 21st, 9:57 PM EDT
Detailed Quote
Previous Close
16.72
Open
16.64
Bid
15.03
Ask
17.00
Day's Range
16.46 - 16.95
52 Week Range
8.330 - 21.03
Volume
479,053
Market Cap
822.21M
PE Ratio (TTM)
29.16
EPS (TTM)
0.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
501,220
Chart
About Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for patients with various debilitating conditions, particularly respiratory and gastrointestinal diseases. Their portfolio includes a range of novel products and drug candidates designed to improve patient outcomes by addressing unmet medical needs. The company places a strong emphasis on advancing its scientific research and collaborations to enhance treatment options and contribute to the overall health and well-being of patients around the world. Read More
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or “the Company”) (NASDAQ: TBPH) for violations of the securities laws.
A beaten-down diagnostics stock is quietly tightening margins and drawing fresh institutional conviction—here’s what that means for long-term investors.
